Drug Trial Radar · NCT04147195
Study of Various Treatments in Non-alcoholic Fatty Liver Disease (NAFLD) Patients Who Have Aspects of Non-alcoholic Steatohepatitis (NASH)
Last checked: Nov 19, 2026Latest source record: Aug 21, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
41
Actual
Start
Jun 4, 2020
Primary completion
Jan 6, 2022
Study completion Jan 6, 2022
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Nov 1, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This clinical study was designed to evaluate the safety, tolerability, pharmacokinetics and efficacy of various single and combination treatments in adult patients with non-alcoholic fatty liver disease (NAFLD) who manifest a non-alcoholic steatohepatitis (NASH)-like biomarker phenotype.
Conditions
- Non-alcoholic Fatty Liver Disease
- Nonalcoholic Steatohepatitis
Interventions
LYS006Drug
5 mg LYS006 capsules orally administered 20 mg b.i.d for 12 weeks
TropifexorDrug
100 ug LJN452 capsules orally administered 200ug once daily for 12 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: From the start of treatment to 28 days after end of treatment, assessed up to maximum duration of 113 Days
Locations
10 sites in 3 countries. Site status is shown where the registry gives one.
Novartis Investigative Site
Coronado, California
Novartis Investigative Site
Los Angeles, California
Novartis Investigative Site
Miami Lakes, Florida
Novartis Investigative Site
Marietta, Georgia
Novartis Investigative Site
Honolulu, Hawaii
Novartis Investigative Site
South Bend, Indiana
Novartis Investigative Site
Morehead City, North Carolina
Novartis Investigative Site
San Antonio, Texas
Novartis Investigative Site
Buenos Aires, Argentina
Novartis Investigative Site
Essen, Nordrhine Westphalia, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.